1,5-Dihydroxyxanthone exhibits the epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitory activity, with the IC50 value of 90.34 nM. It may have anticholinesterase activity on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzym

WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.

Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.

Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of Ys, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.

EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.